Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Medicine Matters diabetes

This video feature is produced by Medicine Matters diabetes and is not supplied or sanctioned by the American Diabetes Association (ADA). 

The educational content contained herein reflects the personal opinion of the experts.

Jay Shubrook declares the following relationships over the past 36 months:

  • Grants/research support: AstraZeneca and Takeda
  • Consulting or advisory role: Intarcia Therapeutics, Novo Nordisk, and Lilly Diagnostics

David Strain  declares the following relationships over the past 36 months:

  • Grants/research support: Novo Nordisk, Takeda, Novartis, Astra-Zeneca.
  • Honoraria: Novo Nordisk, Novartis, Boehringer Ingelheim, Janssen, Eli Lilly, Merck, Pfizer, BMS.
  • Consulting or advisory role: Novartis, Novo-Nordisk.
  • Travel, accommodations, expenses: Astra Zeneca, Novartis.